Worldwide, including USA, UK, Europe, Canada, Australia
Indications and usage:
Yasmin (Drospirenone, Ethinyl Estradiol) is an estrogen/progestin COC, indicated for use by women to prevent pregnancy.
Dosage and administration:
Take one Yasmin tablet daily by mouth at the same time every day.
Tablets must be taken in the order directed on the blister pack.
Dosage forms and strengt:
Yasmin consists of 28 film-coated, biconvex tablets in the following order:
21 yellow tablets, each containing 3 mg drospirenone (DRSP) and 0.03 mg ethinyl estradiol (EE),
7 inert white tablets.
There have been no reports of serious ill effects from Yasmin overdose, including ingestion by children. Overdosage may cause withdrawal bleeding in females and nausea.
DRSP is a spironolactone analogue which has antimineralocorticoid properties. Serum concentration of potassium and sodium, and evidence of metabolic acidosis, should be monitored in cases of overdose.
A high risk of arterial or venous thrombotic diseases
Undiagnosed abnormal uterine bleeding
Breast cancer or other estrogen- or progestin-sensitive cancer
Liver tumors or liver disease
Warnings and precautions:
Vascular risks: stop Yasmin if a thrombotic event occurs. Stop at least 4 weeks before and through 2 weeks after major surgery. Start no earlier than 4 weeks after delivery, in women who are not breastfeeding. COCs containing DRSP may be associated with a higher risk of venous thromboembolism (VTE) than COCs containing levonorgestrel or some other progestins. Before initiating Yasmin in a new COC user or a woman who is switching from a contraceptive that does not contain DRSP, consider the risks and benefits of a DRSP-containing COC in light of her risk of a VTE.
Hyperkalemia: DRSP has antimineralocorticoid activity. Do not use in patients predisposed to hyperkalemia. Check serum potassium concentration during the first treatment cycle in women on long-term treatment with medications that may increase serum potassium concentration.
Liver disease: discontinue Yasmin if jaundice occurs.
High blood pressure: do not prescribe Yasmin for women with uncontrolled hypertension or hypertension with vascular disease.
Carbohydrate and lipid metabolic effects: Monitor prediabetic and diabetic women taking Yasmin. Consider an alternate contraceptive method for women with uncontrolled dyslipidemia.
Headache: evaluate significant change in headaches and discontinue Yasmin if indicated.
Uterine bleeding: evaluate irregular bleeding or amenorrhea.
Adverse reactions, side effects:
The most frequent adverse reactions (>= 2%) are premenstrual syndrome (13.2%), headache /migraine (10.7%), breast pain/tenderness/discomfort (8.3%), nausea/vomiting (4.5%), abdominal pain/tenderness/discomfort (2.3%), mood changes (2.3%).
To report suspected side effects of Yasmin (Drospirenone, Ethinyl Estradiol) 3 mg / 0.03 mg pills contact Bayer pharmaceutical company, or your local FDA.
Drugs or herbal products that induce certain enzymes (for example, CYP3A4) may decrease the effectiveness of COCs or increase breakthrough bleeding. Counsel patients to use a back-up or alternative method of contraception when enzyme inducers are used with COCs.
Nursing mothers: not recommended; can decrease milk production.
Patient counseling information:
Counsel patients that cigarette smoking increases the risk of serious cardiovascular events from COC use, and that women who are over 35 years old and smoke should not use COCs.
Counsel patients that the increased risk of VTE compared to non-users of COCs is greatest after initially starting a COC or restarting (following a 4-week or greater pill-free interval) the same or a different COC.
Counsel patients about the information regarding the risk of VTE with DRSP-containing COCs compared to COCs that contain levonorgestrel or some other progestins.
Counsel patients that Yasmin does not protect against HIV infection (AIDS) and other sexually transmitted diseases.
Counsel patients on warnings and precautions associated with COCs.
Counsel patients that Yasmin contains DRSP. Drospirenone may increase potassium. Patients should be advised to inform their healthcare provider if they have kidney, liver or adrenal disease because the use of this medication in the presence of these conditions could cause serious heart and health problems. They should also inform their healthcare provider if they are currently on daily, long-term treatment (NSAIDs, potassium-sparing diuretics, potassium supplementation, ACE inhibitors, angiotensin-II receptor antagonists, heparin or aldosterone antagonists) for a chronic condition.
Inform patients that Yasmin is not indicated during pregnancy. If pregnancy occurs during treatment with Yasmin, instruct the patient to stop further intake.
Counsel patients to take one tablet daily by mouth at the same time every day. Instruct patients what to do in the event pills are missed.
Counsel patients to use a back-up or alternative method of contraception when enzyme inducers are used with COCs.
Counsel patients who are breastfeeding or who desire to breastfeed that COCs may reduce breast milk production. This is less likely to occur if breastfeeding is well established.
Counsel any patient who starts COCs postpartum, and who has not yet had a period, to use an additional method of contraception until she has taken a yellow tablet for 7 consecutive days.
Counsel patients that amenorrhea may occur. Rule out pregnancy in the event of amenorrhea in two or more consecutive cycles.
Where to buy Yasmin online:
To purchase Yasmin (Drospirenone, Ethinyl Estradiol) 3 mg / 0.03 mg tablets from reliable online pharmacies and drugstores at low prices please use resources described above on this webpage.
Here is a list of popular medications containing drospirenone 3 mg and ethinyl estradiol 0.03 mg as main active pharmaceutical ingredients; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers: